ALBANY, N.Y., July 18, 2017 (GLOBE NEWSWIRE) — AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported fourth quarter and full year financial results for the 2017 fiscal year ended May 31, 2017.
“The quarter, and year, reflect a commitment to strengthening our business, improving our core operational efficiency and making strategic decisions that will enable long-term, sustainable top-line growth as we outlined in our recent Investor Day, held in April,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “Over the course of the year, we have worked hard to become a profitable, efficiently run operating company. We ended the year with record high Adjusted EPS of $0.73 and free cash flow of more than $52 million. These are important measures as we look at opportunities to spur growth in fiscal year 2018 and beyond.”